{"id":1951,"date":"2026-09-10T06:03:00","date_gmt":"2026-09-09T21:03:00","guid":{"rendered":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-10-vexas-ripk3-rnase1-en\/"},"modified":"2026-09-10T06:03:00","modified_gmt":"2026-09-09T21:03:00","slug":"2026-09-10-vexas-ripk3-rnase1-en","status":"publish","type":"briefing","link":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-10-vexas-ripk3-rnase1-en\/","title":{"rendered":"A cell model reproduced VEXAS severity differences, nominating RIPK3 and RNASE1"},"content":{"rendered":"

2026-09-10 06:03 KST<\/strong><\/p>\n

Researchers reproduced differences in inflammation and cell death between acquired UBA1 mutation types in VEXAS syndrome using patient blood and a new human-monocyte model. RIPK3 signalling and blood RNASE1 tracked with severity.<\/p>\n

This does not show that a RIPK3 inhibitor treats patients. Inhibition mainly reduced pathological features in cells, while RNASE1 remains a biomarker candidate requiring independent validation.<\/p>\n

What is VEXAS?<\/h2>\n

A rare disease, usually in older men, caused by acquired UBA1 mutations in blood-forming cells, producing systemic inflammation and marrow problems.<\/p>\n

What was compared?<\/h2>\n

The team analysed deep data from 79 patients and mutation-specific expression, then introduced variants into human monocytes to test whether differences reappeared.<\/p>\n

\"A
This AI-generated image explains the topic; it is not a photograph of the actual site, experiment, animal or fossil.<\/figcaption><\/figure>\n

RIPK3<\/h2>\n

Blocking the pathway sharply reduced inflammatory signalling and cell death in the model. Cell experiments cannot establish dose, adverse effects or whole-body benefit.<\/p>\n

RNASE1<\/h2>\n

Blood expression correlated strongly with an activity score. Correlation supports a candidate marker, not a stand-alone test or proof of cause.<\/p>\n

Next steps<\/h2>\n

Prospective independent cohorts, comparison with current care and safety testing of RIPK3 targeting are needed. Patients should not change treatment from this study alone.<\/p>\n

Primary source and independent checks<\/h2>\n

\uc694\ucf54\ud558\ub9c8\uc2dc\ub9bd\ub300 \ubc1c\ud45c<\/a><\/p>\n

Arthritis & Rheumatology \uac8c\uc7ac \uc11c\uc9c0<\/a><\/p>\n

\uc120\ud589 \uacf5\uac1c \uc6d0\uc790\ub8cc<\/a><\/p>\n

Read in other languages<\/h2>\n

\ud55c\uad6d\uc5b4<\/a> \u00b7 English<\/a> \u00b7 Espa\u00f1ol<\/a> \u00b7 \u65e5\u672c\u8a9e<\/a> \u00b7 Ti\u1ebfng Vi\u1ec7t<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Patient blood and human monocytes linked inflammation to UBA1 mutation type. This is not treatment approval or evidence of clinical efficacy.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"class_list":["post-1951","briefing","type-briefing","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing\/1951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing"}],"about":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/types\/briefing"}],"wp:attachment":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/media?parent=1951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}